Article Versions Notes

Feng W-H, Chang Y-C, Lin Y-H, Chen H-L, Chen C-Y, Lin T-H, Lin T-C, Chang C-T, Kuo H-F, Chang H-M, et al. P2Y12 Inhibitor Monotherapy versus Conventional Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Meta-Analysis. Pharmaceuticals. 2023; 16(2):232. https://doi.org/10.3390/ph16020232

Feng, Wen-Han, Yong-Chieh Chang, Yi-Hsiung Lin, Hsiao-Ling Chen, Chun-Yin Chen, Tsung-Han Lin, Tzu-Chieh Lin, Ching-Tang Chang, Hsuan-Fu Kuo, Hsiu-Mei Chang, and et al. 2023. "P2Y12 Inhibitor Monotherapy versus Conventional Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Meta-Analysis" Pharmaceuticals 16, no. 2: 232. https://doi.org/10.3390/ph16020232

Feng, W.-H., Chang, Y.-C., Lin, Y.-H., Chen, H.-L., Chen, C.-Y., Lin, T.-H., Lin, T.-C., Chang, C.-T., Kuo, H.-F., Chang, H.-M., & Chu, C.-S. (2023). P2Y12 Inhibitor Monotherapy versus Conventional Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Meta-Analysis. Pharmaceuticals, 16(2), 232. https://doi.org/10.3390/ph16020232